Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.

Blood advances - 28 May 2024

Montesinos Pau, Fathi Amir T, de Botton Stéphane, Stein Eytan M, Zeidan Amer M, Zhu Yue, Prebet Thomas, Vigil Carlos E, Bluemmert Iryna, Yu Xin, DiNardo Courtney D

Abstract excerpt

ABSTRACT: Treatment with enasidenib, a selective mutant isocitrate dehydrogenase isoform 2 (IDH2) inhibitor, has been associated with the development of differentiation syndrome (DS) in patients with acute myeloid leukemia (AML). Studies on the incidence and clinical features of DS are limited in this setting, and diagnosis is challenging because of nonspecific symptoms. This study assessed the incidence,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aminopyridines

Share to Cell Differentiation

Share to Clinical Trials as Topic

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 38507688
DOI: 10.1182/bloodadvances.2023011914
PMCID: PMC11131052

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.PMID 38507688Read ↗

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.Semantic proximity Read ↗

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.Semantic proximity Read ↗

Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.Semantic proximity Read ↗

Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic ParadigmsSemantic proximity Read ↗

Enasidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

IDH Inhibitors in AML-Promise and Pitfalls.Semantic proximity Read ↗

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.Semantic proximity Read ↗

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Semantic proximity Read ↗

Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Semantic proximity Read ↗

Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.